Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Irida Kastrati

Has grant

Associate Professor with Tenure

Loyola University Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cell Biology Cell Biology professors in United States

Recent Grants

Grant: Close

Exploit Dimethyl Fumarate to Uncover Druggable Vulnerabilities and Prevent Recurrence of ER+ Breast Cancers

Open Date: 2017-10-01

Close Date: 2018-09-01

Grant: Close

SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.

Open Date:

Close Date:

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2020

Collaborators (1)

Alan Diamond

Professor

University of Chicago

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Irida Kastrati

Research Interests

Explore related searches

Recent Grants

Articles (10)

Crosstalk between SELENOF and the unfolded protein response in breast epithelium dictates cell fate

SELENOF and its translational inhibitor EIF4A3 are differentially expressed in colon cancer.

Contributions of selenoproteins to breast cancer etiology and racial disparity.

Unravelling the anti-cancer mechanisms elicited by non-covalent thioredoxin reductase inhibitors for triple negative breast cancer therapy.

Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers

SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells

Distinct Roles of SELENOF in Different Human Cancers

Selenium and breast cancer – An update of clinical and epidemiological data

SELENOF is a new tumor suppressor in breast cancer

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Collaborators (1)

Alan Diamond

Make your next move.